5a-Reductase is an NADPH-dependent enzyme responsible for the conversion of testosterone to dihydrotestosterone (DHT), an active agonist for androgen receptors. Benign prostatic hyperplasia (BPH), skin disorders such as acne, male pattern baldness and hirsutism are androgen-related disorders, associated with elevated levels of DHT.
5a-Reductase is an NADPH-dependent enzyme responsible for the conversion of testosterone to dihydrotestosterone (DHT), an active agonist for androgen receptors. Benign prostatic hyperplasia (BPH), skin disorders such as acne, male pattern baldness and hirsutism are androgen-related disorders, associated with elevated levels of DHT.
5) As a consequence, a 5a-reductase inhibitor is expected to provide a potential treatment for various androgen-related disorders. Several 5a-reductase inhibitors have been reported, 6, 7) including both steroidal inhibitors such as finasteride 6a) and epristeride, 6b) and nonsteroidal inhibitors such as ONO-3805 7a)
( Fig. 1) . Following the discovery of these inhibitors, the existence of two different 5a-reductase isozymes, type 1 and type 2 5a-reductase, has been reported in humans and rats. [8] [9] [10] The type 1 enzyme is normal in men with congenital 5a-reductase deficiency and is expressed in skin tissue throughout the body that has an optimal pH of between 6 and 9. The type 2 enzyme is defective in men with congenital 5a-reductase deficiency and is the dominant form of the enzyme in genital tissue, including prostate that has an optimal pH of about 5.5. However, the exact physiological roles of these isozymes has yet to be fully elucidated. Steroidal inhibitors, for example, finasteride, have been shown to be clinically effective for treatment of BPH, however the possibility of adverse effects due to their steroidal structures remains. 11) On the other hand, nonsteroidal inhibitors have not shown clinical efficacy for the treatment of BPH. Finasteride showed strong inhibitory activity (IC 50 ϭ4.1 nM) 12) for human prostatic 5a-reductase, whereas ONO-3805 showed moderate activity (IC 50 ϭ538 nM) 12) which might not be sufficient to show clinical efficacy. We considered that a more potent nonsteroidal inhibitor of human prostatic 5a-reductase than ONO-3805 could show clinical efficacy for the treatment of BPH and reduce the potential for side effects compared to steroidal inhibitors.
In our previous studies on novel human prostatic 5a-reductase inhibitors, we found the biphenyl-4-yloxy benzoic acid derivative, YM-31758 (1), which showed potent inhibitory activity with an IC 50 value of 0.87 nM. 1) During the course of this study, we found that it is favorable for high potency to have a hydrophobic substituent such as a phenyl group at a position from the carboxyl group in the range of 9-11 Å through the benzene ring juncture. These results suggested that it may be possible to find a more potent inhibitor against human prostatic 5a-reductase through modification of the biphenyl-4-yloxy group in YM-31758. In this study, we focused on modification of the biphenyl-4-yloxy group. A 1H-indole-5-yloxy group as a substituent at the 4-position of the benzoic acid moiety was newly designed as described in Fig. 1 . We report here the synthesis and the structure-activity relationships of the indole derivatives 2.
Chemistry
2-Phenyl-1H-indole derivatives (2a, 2b) were prepared as shown in Chart 1. The demethylation of compound 3 was performed using BBr 3 to give compound 4, which was converted to compound 5 by alkylation with 3-chloro-4-fluorobenzonitrile. Compound 2a was obtained by hydrolysis with KOH. Compound 2b was prepared by the N-methylation of compound 5 in the presence of KOH in dimethyl sulfoxide (DMSO) with methyl iodide 13) and subsequent hydrolysis with KOH. The 3-benzyl-1-methyl-1H-indole derivative 2c was prepared as shown in Chart 2. After methylation of compound 7, benzoylation was carried out by the Vilsmeier method to give compound 8. Debenzylation and reduction of the carbonyl group were performed using catalytic hydrogenation in the presence of Pd-C to afford compound 9, which was converted to the benzoic acid derivative 2c in two steps. The 1-alkyl-1H-indole derivatives (2d-2u) were prepared from compound 7 by three synthetic methods (Methods A, B and C) as described in Chart 3. Compound 11 was obtained by debenzylation of 7 in the presence of Pd-C and subsequent alkylation with 3-chloro-4-fluorobenzonitrile. NAlkylation of 11 was performed using KOH in DMSO to give compound 13, which was then hydrolyzed with KOH to give the benzoic acid derivatives 2f-2i and 2l (Method A). Compound 12, prepared by the N-alkylation of 7 with an alkyl halide and subsequent debenzylation in the presence of Pd-C, was alkylated with 3-chloro-4-fluorobenzonitrile to afford compound 13, which was hydrolyzed with KOH to give the benzoic acid derivatives 2d, 2e and 2q (Method B). Compound 7 was acylated with chloroethylformate followed by debenzylation to afford 14. Alkylation of 14 with 3-chloro-4-fluorobenzonitrile afforded 15, which was hydrolyzed with KOH to give the benzoic acid derivative 16. N-Alkylation of 16 was also carried out in the presence of KOH in DMSO to afford the benzoic acid derivatives 2j, 2k, 2m-2p and 2r-2u (Method C).
Results and Discussion
The inhibitory activities of the indole derivatives were evaluated on the basis of the ability to inhibit 5a-reductase in human prostate at pH 5.5 which is optimal for the activity of the type 2 enzyme. The results are described in Tables 1-4. In our previous paper, we found that for high potency it is favorable to have a phenyl group at a position from the carboxyl group in the range of 9-11 Å for phenoxy benzoic acid derivatives. Initially, the favorable position for the phenyl group on the indole ring was investigated as shown in Table 1 . Compound 2a, having an acidic proton at the 1-position on the indole ring, showed in a loss of activity, while the 1-methyl-2-phenyl-1H-indole derivative 2b showed potent inhibitory activity with an IC 50 of 3.4 nM. An acidic proton in this position was found to be incompatible with potent inhibitory activity. The 3-benzyl-1-methyl-1H-indole derivative 2c resulted in decreased activity, while the 1-benzyl-1H-indole derivative 2d showed strong potency with an IC 50 of 0.44 nM. These findings suggested that the position of the phenyl group is important for high potency. In order to investigate the correlation between distance and inhibitory activity, optimized structures for the indole derivatives 2b-2d were calculated by a systematic search and minimization using the molecular modeling program Sybyl, version 6.3, and the distances between the carbon of the carboxyl group and centroid of the phenyl group (benzene ring A) were calculated from the optimized structures. The calculated data and the optimized structures of 2b-2d are shown in Table 2 and Fig. 2 , respectively. The distances for the potent compounds 2b and 2d are in the range of 9-11 Å, with values of 11.367 Å and 8.705 Å, respectively.
On the other hand, the reduced potent compound 2c is a non-linear compound, and the position of the benzene ring A is probably too close to the carboxyl group, with a value of 4.657 Å, to show potent inhibitory activity. The 1-benzyl derivative 2d showed more potent inhibitory activity compared to 2b or YM-31758, suggesting that the 1-benzyl-1H-indole group of 2d is more flexible compared to the 1-methyl-2-phenyl-1H-indole group of 2b or the biphenyl group of YM-31758 and the position of the phenyl group in 2d may be more favorable for hydrophobic interaction with the enzyme compared to the position of the phenyl group in 2b or YM-31758.
Next, we focused our efforts on modification of the benzyl group of compound 2d. These results are summarized in Table 3 . Concerning the distance between the indole ring and the phenyl group, the 3-phenylpropyl derivative 2e retained high potency, while the 5-phenylpentyl derivative 2f showed reduced inhibitory activity. These results suggested that the inhibitory activity is affected by the bulkiness of the substituent, i.e., the 3-phenylpropyl group is tolerant but the 5-phenylpentyl group is too bulky. Concerning the substituent on the benzyl group, the 4-methylbenzyl derivative 2i re- sulted in a slight increase in activity compared to the 2-methylbenzyl derivative 2g or 3-methylbenzyl derivative 2h, suggesting that the 4-position is the favorable position for modification of the benzyl group. Replacement of the methyl group in compound 2i with a cyano group (2k) or methoxy group (2l) retained high potency, while replacement with a propyl group (2j) or phenoxy group (2m) resulted in a slight loss of inhibitory activity, suggesting that the propyl and phenoxy groups are too bulky for high potency. Furthermore, the effect of another aromatic substituent such as a furan ring or thiophene ring instead of the benzene ring in compound 2d
was investigated. The furfuryl derivative 2n, the 2-thienylmethyl derivative 2o and the 3-thienylmethyl derivative 2p showed strong inhibitory activities with IC 50 values below 0.5 nM, suggesting that these heteroaromatic rings may enhance the inhibitory activity by an interaction with a hydrophobic pocket in the enzyme. Finally, the inhibitory activities of compounds having no aromatic ring at the 1-position of the indole ring was investigated. The methyl derivative 2q and octyl derivative 2s showed reduced inhibitory activities, while the butyl derivative 2r, cyclopropylmethyl derivative 2t and prenyl derivative 2u retained high potency with IC 50 val- ues below 1 nM. These results demonstrated that the inhibitory activity is affected by the bulkiness of the substituent and an aromatic ring at the 1-position of the indole ring is not essential for high potency. This new series of indole derivatives 2b-2u was further evaluated for rat prostatic 5a-reductase inhibitory activities in order to investigate in vivo inhibitory activity. Compound 1 did not inhibit the rat enzyme, whereas finasteride and (Ϯ)-ONO-3805 showed inhibitory activities with IC 50 values of 13 nM and 2.6 nM, respectively, as shown in Table 4 . Except for compound 2m, none of these indole derivatives showed potent inhibitory activity toward the rat enzyme with an IC 50 below 100 nM. Compound 2m showed moderate inhibitory activity against the rat enzyme with an IC 50 value of 73 nM (Table 4 ) which may not be sufficient to show inhibitory activity in an in vivo model such as the castrated young rat model. 14) These findings suggest that these indole derivatives 2b-2u are selective human prostatic 5a-reductase inhibitors.
Conclusions
In order to prepare a novel potent inhibitor against human prostatic enzymes, we modified the biphenyl-4-yl group of YM-31758 to the 1H-indol-5-yl group. Consequently, we have identified a new series of indole derivatives as potent human prostatic 5a-reductase inhibitors. Particularly, compounds 2d (YM-32906), 2l and 2n-2p showed potent inhibitory activities with IC 50 values below 0.5 nM. Replacement of the benzyl group in compound 2d with a 4-phenoxybenzyl group (2m) resulted in an increase in the inhibitory activity against the rat enzyme. Further efforts to discover novel nonsteroidal inhibitors possessing high potency for both human and rat prostatic 5a-reductases are on going.
Experimental
Melting points were recorded on a Yanaco MP-3 melting point apparatus and are uncorrected. 1 H-nuclear magnetic resonance ( 1 H-NMR) spectra were recorded on a JEOL FX-90, JNM-LA 300, JNM-LA 400, JNM-GX 400 or JNM-GX 500 spectrometer with tetramethylsilane as an internal standard. Mass spectra (MS) were recorded on a Hitachi M-80 (electron impact (EI)) or JEOL JMS-DX300 (FAB) mass spectrometer. Elemental analysis was performed with a Yanaco MT-5. Column chromatography was carried out on silica gel (Wakogel C-200). Unless otherwise noted, all reagents and solvents obtained from commercial suppliers were used without further purification. In general, the organic extract was dried over anhydrous Na 2 SO 4 or MgSO 4 , and the organic solvent was evaporated under reduced pressure. All non-aqueous reactions were performed in dry glassware under an atmosphere of dry Ar. The three-dimensional structures of the molecules were constructed using the molecular modeling program Sybyl (version 6.3) on an Indigo Elan workstation (Silicon Graphics Inc., Mountain View, CA). Each structure was energy-minimized using the Tripos force field with the default convergence criteria.
2-Phenyl-1H-indole-5-ol (4) To a solution of 3 (670 mg, 3.00 mmol) in 5 ml of CH 2 Cl 2 , BBr 3 (1.0 M in CH 2 Cl 2 ; 9.0 ml, 9.0 mmol) was added dropwise at Ϫ78°C, and then the mixture was stirred at room temperature for 13 h. The reaction was quenched with ice-water and extracted with AcOEt. The organic layer was washed with water and brine, dried and concentrated. The residue was recrystallized from EtOH to give 4 (459 mg, 73%). 
3-Chloro-4-[(2-phenyl-1H-indol-5-yl)oxy]benzonitrile (5)
A mixture of 4 (450 mg, 2.15 mmol), 3-chloro-4-fluorobenzonitrile (334 mg, 2.15 mmol) and K 2 CO 3 (442 mg, 3.20 mmol) in 3 ml of DMSO was stirred at room temperature for 6 h. After dilution with AcOEt, the reaction mixture was washed with water and brine, dried and concentrated. The residue was recrystallized from AcOEt-EtOH to give 5 (595 mg, 80%). 
3-Chloro-4-[(2-phenyl-1H-indol-5-yl)oxy]benzoic Acid (2a)
To a solution of 5 (190 mg, 0.55 mmol) in 5 ml of EtOH, 1.5 ml of 8 N KOH aqueous solution was added, and the mixture was refluxed for 4 h. The reaction mixture was acidified with 3 N HCl aqueous solution and extracted with AcOEt. The extract was washed with water and brine, dried and concentrated, and the residue was recrystallized from AcOEt to give 2a (150 mg, 75%): mp 268-270°C. 
3-Chloro-4-[(1-methyl-2-phenyl-1H-indol-5-yl)oxy]benzoic Acid (2b)
A mixture of 5 (207 mg, 0.60 mmol), methyl iodide (170 mg, 1.2 mmol) and KOH (67 mg, 1.2 mmol) in 1.0 ml of DMSO was stirred at room temperature for 1.5 h. The reaction was quenched with water and extracted with AcOEt. The organic layer was washed with water and brine, dried and concentrated to give 3-chloro-4-[(1-methyl-2-phenyl-1H-indol-5-yl)oxy]benzonitrile (6) (211 mg). This crude oil 6 (190 mg) was dissolved in 2.5 ml of EtOH, then 1.0 ml of 8 N KOH aqueous solution was added, and the mixture was refluxed for 5 h. The reaction mixture was acidified with 2 N HCl aqueous solution and extracted with AcOEt. The extract was washed with water and brine, dried and concentrated, and the residue was recrystallized from AcOEt to give 2b (144 mg, 72%): mp 260-263°C. 1 
.
5-Benzyloxy-1-methyl-1H-indol-3-yl Phenyl Ketone (8)
A mixture of 5-benzyloxy-1H-indole (7) (4.02 g, 18.0 mmol), methyl iodide (5.11 g, 36.0 mmol) and KOH (2.0 g, 36.0 mmol) in 15 ml of DMSO was stirred at room temperature for 30 min. The reaction was quenched with water and extracted with AcOEt. The organic layer was washed with water and brine, dried and concentrated to give 5-benzyloxy-1-methyl-1H-indole (4.06 g). To a solution of 1-benzoylpyrrolidine (1.05 g, 6.0 mmol) in 6 ml of 1,2-dichloroethane, 1.68 ml of POCl 3 was added dropwise under refluxing. Stirring was continued for 40 min at this temperature, then the crude 5-benzyloxy-1-methyl-1H-indole (1.42 g) in 4 ml of 1,2-dichloroethane was added, and the mixture was refluxed for 6 h. The reaction was quenched with water, then neutralized with 1 N NaOH aqueous solution and extracted with AcOEt. The organic layer was washed with water and a saturated aqueous solution of NaCl, dried and concentrated. The residue was purified by silica gel column chromatography (eluent; hexane : AcOEtϭ2 : 3) to give 8 (1.33 g, 65% 
3-Benzyl-1-methyl-1H-indol-5-ol (9)
To a solution of 8 (478 mg, 1.40 mmol) in 16 ml of AcOEt-EtOH-AcOH (10 : 3 : 3), 10% Pd-C (50 mg) was added. The flask was then placed under a hydrogen atmosphere and stirred at room temperature for 2 d. The catalyst was removed by filtration and the filtrate was concentrated. The residue was purified by silica gel column chromatography (eluent; hexane : AcOEtϭ4 : 1) to give 9 (155 mg, 47%). 
Method A. 3-Chloro-4-(1H-indol-5-yloxy)benzonitrile (11)
A mixture of 7 (4.47 g, 20.0 mmol), 10% Pd-C (500 mg) and ammonium formate (10.09 g, 160 mmol) in 100 ml of EtOH was stirred at room temperature for 3 h. The catalyst was removed by filtration and the filtrate was concentrated to give 1H-indole-5-ol (10) (2.89 g). This crude oil 10 (2.89 g) was dissolved in 50 ml of N,N-dimethylformamide (DMF), then 3-chloro-4-fluorobenzonitrile (3.27 g, 21.2 mmol) and K 2 CO 3 (6.91 g, 50.0 mmol) were added, and the mixture was heated at 80°C for 16 h. The reaction was quenched with water and extracted with AcOEt. The organic layer was washed with water and brine, dried and concentrated. The residue was purified by silica gel column chromatography (eluent; hexane : Et 2 Oϭ5 : 1) to give 11 (1.08 g, 29%). 
3-Chloro-4-{[1-(5-phenylpentyl)-1H-indol-5-yl]oxy}benzonitrile (13f)
To a suspension of KOH (292 mg, 5.21 mmol) in DMSO (3 ml), 11 (350 mg, 1.30 mmol) was added and the mixture stirred at room temperature for 40 min, and 5-phenylpentyl bromide (355 mg, 1.56 mmol) in DMSO (1 ml) was added dropwise at room temperature. Stirring was continued for 2 h at this temperature. The reaction was quenched with water and extracted with AcOEt. The organic layer was washed with water and brine, dried and concentrated. The residue was purified by silica gel column chromatography (eluent; hexane : Et 2 Oϭ95 : 5) to give 13f (337 mg, 62%). 
3-Chloro-4-{[1-(5-phenylpentyl)-1H-indol-5-yl]oxy}benzoic Acid (2f)
Compound 13f was hydrolyzed in the same manner as described for compound 2a to give 2f: mp 144-145°C. 1 Benzyl-1H-indol-5-ol (12d) To a suspension of KOH (13.5 g, 240 mmol) in DMSO (100 ml), 7 (13.4 g, 60.0 mmol) was added and the mixture stirred at room temperature for 50 min, and benzyl bromide (10.8 g, 63.0 mmol) in DMSO (50 ml) was added dropwise at room temperature. Stirring was continued for 3 h at this temperature and the reaction was then quenched with water and extracted with AcOEt. The organic layer was washed with water and brine, dried and concentrated, and the residue recrystallized from EtOH to give 1-benzyl-5-benzyloxy-1H-indole (16.0 g, 85%) . To a suspension of 1-benzyl-5-benzyloxy-1H-indole (16.0 g, 51.0 mmol) in 300 ml of EtOH, 10% Pd-C (1.60 g) and ammonium formate (25.7 g, 408 mmol) was added, and the mixture was stirred at room temperature for 3 h. The catalyst was removed by filtration and the filtrate was concentrated. The residue was extracted with AcOEt and the extract was washed with 1 N HCl aqueous solution, water and brine, then dried and concentrated to give 12d (10.9 g, 96%). of NaH was added at 0°C and the mixture stirred at 60°C for 1 h. Ethyl chloroformate (15.2 g, 140 mmol) was added dropwise at 0°C, and the mixture was stirred at room temperature for 15 h. The reaction was quenched with water and extracted with AcOEt. The organic layer was washed with water and brine, dried and concentrated. The residue was purified by silica gel column chromatography (eluent; hexane : CHCl 3 ϭ1 : 1) to give ethyl 5-benzyloxy-1H-indole-1-carboxylate (28.5 g, 72%). This intermediate (8.98 g, 30.4 mmol) was dissolved in EtOH (180 ml), then 10% Pd-C (0.9 g) and ammonium formate (15.3 g, 243 mmol) were added, and the mixture was stirred at room temperature for 45 min. The catalyst was removed by filtration and the filtrate concentrated, and the residue extracted with AcOEt. The extract was washed with 1 N HCl aqueous solution, water and brine, then dried and concentrated. The residue was purified by silica gel column chromatography (eluent; CH 2 Cl 2 : etherϭ98 : 2) to give 14 (4.90 g, 79%). was added dropwise at room temperature. Stirring was continued for 2 h at this temperature and the reaction was then quenched with water and extracted with AcOEt. The organic layer was washed with water and brine, dried and concentrated. The residue was purified by silica gel column chromatography (eluent; CHCl 3 ) and recrystallized from EtOH to give 2j (113 mg, 52%): mp 168-171°C. 1 
. Authentic Materials The 5a-reductase inhibitors finasteride 6a) and (Ϯ)-ONO-3805 7a) were synthesized in our company according to the methods described in the literature.
Biological Methods. Preparation of 5a a-Reductases from Rat Prostate and Human Prostate Male Wistar rats 8-12 weeks of age (Charles River Japan Inc. Atsugi, Japan) were sacrificed and the ventral prostates were removed. The prostatic tissues were rinsed with ice-cold saline and minced with scissors. Unless specified, all the following procedures were carried out at 4°C. The minced tissues were homogenized with a Polytron homogenizer (Kinematica GMBH, Lucerne, Switzerland) in 3 tissue volumes of 20 mM sodium phosphate buffer pH 7.0 containing 0.25 M sucrose and 0.1 mM dithiothreitol (DTT). The homogenate was centrifuged at 10000 g for 10 min, and the resulting supernatant was centrifuged again at 140000 g for 60 min. The pellets were resuspended in 40 mM sodium phosphate buffer pH 6.5. The suspension was stored at Ϫ80°C until use.
Human prostatic tissues from BPH patients who received a transurethral prostatectomy were kindly provided by Dr. T. Tahara at Yamato Hospital, Tokyo, Japan, and stored at Ϫ80°C until preparation of the enzyme fractions. The frozen prostatic tissues were minced with scissors and homogenized with a Polytron homogenizer in 3 tissue volumes of 10 mM Tris-HCl buffer pH 7.0 containing 0.33 M sucrose, 1 mM DTT and 1 mM NADPH. The homogenate was centrifuged at 1000 g for 5 min. The supernatant was centrifuged at 11000 g for 20 min, and the resulting supernatant was centrifuged again at 140000 g for 60 min. The resulting pellet was resuspended in 10 mM Tris-HCl buffer pH 7.0 and stored at Ϫ80°C until use.
5a a-Reductase Assay in Vitro 5a-reductase activities were assayed according to the method described by Liang et al. 15) with a minor modification. Briefly, the reaction solutions contained in a final volume of 0.5 ml : 1 mM [4-14 C] testosterone, 1 mM DTT, 50 mM NADPH, 50 mM buffer (Tris-HCl pH 6.5, for the rat prostate enzyme; Tris-citrate pH 5.0, for the human prostate enzyme) and the enzyme fractions. To identify the inhibitory effect of the drugs, various concentrations of the test compounds were added in 5 ml DMSO (final conc. 1%). The reaction solutions in duplicate were incubated at 37°C for 60 min, and the reaction was terminated by addition of 2.0 ml cold AcOEt containing 10 mg testosterone, 5a-DHT, 4-androstene-3,17-dione, 5a-androstan-3a,17b-diol and 5a-androstan-3,17-dione as the standards. The organic phase was separated by centrifugation, evaporated under N 2 gas and resuspended with 40 ml AcOEt. 20 ml of AcOEt was spotted on the TLC plate and separated twice by AcOEt/cyclohexane (1 : 1) as the developing solvent. The steroid standards were located by UV (254 nm) and by spraying with a 1% CeSO 4 -10% H 2 SO 4 solution followed by heating. The regions containing 5a-reduced metabolites (5a-DHT, 5a-androstan-3a, 17b-diol and 5a-androstan-3,17-dione) were cut from the TLC plate, soaked in 5 ml of Aquasol-2 and the radioactivity was counted by a scintillation counter. The IC 50 values for 5a-reductase activity were obtained from the linear line drawn by least-squares fitting methods.
